Download Files:
ACY-738
$120 – $780
Products Details
Product Description
– ACY-738 is a potent, selective and orally-bioavailable HDAC6 inhibitor, with an IC50 of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC50s of 94, 128, and 218 nM.
Web ID
– HY-19327
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C14H14N4O2
References
– [1]Jochems J, et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology. 2014 Jan;39(2):389-400.|[2]Regna NL, et al. Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. Clin Immunol. 2016 Jan;162:58-73.|[3]Mithraprabhu S, et al. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br J Haematol. 2013 Aug;162(4):559-62.
CAS Number
– 1375465-91-0
Molecular Weight
– 270.29
Compound Purity
– 99.12
SMILES
– O=C(NO)C(C=N1)=CN=C1NC2(CC2)C3=CC=CC=C3
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 32 mg/mL
Target
– HDAC
Isoform
– HDAC1;HDAC2;HDAC3;HDAC6
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
